LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Stock List・Incyte Corp
Search

Incyte Corp

Closed

SectorHealthcare

100.79 -1.52

Buy

Price update 8 Jun 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

98.54

Max

104.46

Key metrics

By Trading Economics

Income

4.1M

303M

Sales

-234M

1.3B

P/E

Sector Avg

13.501

49.888

EPS

1.81

Profit margin

23.834

Employees

2,844

EBITDA

-47M

368M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+6.27% upside

Dividends

By Dow Jones

Next Earnings

28 Jul 2026

Market Stats

By TradingEconomics

Market Cap

49M

19B

Previous open

102.31

Previous close

100.79

News Sentiment

By Acuity

47%

53%

151 / 344 Healthcare

Incyte Corp Chart

Past performance is not a reliable indicator of future results.

Related News

8 Jun 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

DJ

Read

8 Jun 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

DJ

Read

8 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

DJ

Read

8 Jun 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

DJ

Read

8 Jun 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

DJ

Read

8 Jun 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

8 Jun 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

DJ

Read

8 Jun 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

DJ

Read

8 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Read

8 Jun 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

DJ

Read

8 Jun 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

DJ

Read

8 Jun 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

DJ

Read

8 Jun 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

DJ

Read

8 Jun 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

DJ

Read

8 Jun 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

DJ

Read

8 Jun 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

DJ

Read

8 Jun 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

8 Jun 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

DJ

Read

8 Jun 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

DJ

Read

8 Jun 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

DJ

Read

8 Jun 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

DJ

Read

8 Jun 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

DJ

Read

8 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Read

8 Jun 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

DJ

Read

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

DJ

Read

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

DJ

Read

8 Jun 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

8 Jun 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

DJ

Read

8 Jun 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

DJ

Read

8 Jun 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

DJ

Read

Peer Comparison

Price change

Incyte Corp Forecast

Price Target

By TipRanks

6.27% upside

12 Months Forecast

Average 108.8 USD  6.27%

High 135 USD

Low 75 USD

Based on 18 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

8

Buy

9

Hold

1

Sell

Based on 18 analysts giving stock ratings to Incyte Corp - Dist in the past 3 months.

Sentiment

By Acuity

151 / 344 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Other stocks from the sector

LLY

Eli Lilly and Co.

1,144.58

↑ +1.28%

JNJ

Johnson and Johnson

232.3

↓-0.15%

ABBV

AbbVie Inc

222.66

↓-2.06%

UNH

UnitedHealth Group Inc

405.72

↑ +1.35%

MRK

Merck & Co Inc.

119.23

↓-1.41%
help-icon Live chat